Form 51-102F3
Material Change Report

Item 1 Name and Address of Company

Biocure Technology Inc. (the **"Company"**)
950-1130 West Pender Street
Vancouver, B.C. V6E 4A4

Item 2 Date of Material Change

October 16, 2018

Item 3 News Release

A news release was disseminated on October 16, 2018 through the facilities of Stockwatch.

Item 4 Summary of Material Change

The Company announces the results of the Pre-Clinical Trial for safety and toxicity of CAR-T cells based treatment for Acute Lymphocytic Leukemia.

Item 5 Full Description of Material Change

The trial results demonstrated a complete remission of the cancerous cells within 7 and 28 days from the injection of reengineered CAR-T cells into a mouse. The study further showed encouraging results as no toxicity symptoms rose from the high-volume injection. BioCure has performed the trial via its wholly owned subsidiary BiocurePharm in collaboration with Pharos Vaccine with the assistance of Osong Medical Innovation Foundations as the trial CRO (Contract Research Organization) and Croen Corp. who led the toxicity tests under GLP (Good Laboratory Practice) standards.

Biocure completed the safety test of a Biodistribution analysis study and toxicity study for single dose intravenous injection as per the Korea FDA guidelines.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

Item 7 Omitted Information

No information has been omitted on the basis that it is confidential information.

Item 8 Executive Officer

Sang Mok Lee is knowledgeable about the material change and the Report and may be contacted at 604.609.7146.

Item 9 **Date of Report**

March 26, 2019